WSJ discussion of AMGN and PRCS Drug Candidates
This WSJ article sounds like really good news, but I feel that the market size for prostate cancer and endometriosis is estimated on the low side.
<<With Praecis Pharmaceuticals Inc. (PRCS), Amgen expects to have FDA approval of abarelix, a treatment for prostate cancer and endometriosis. Amgen anticipates this therapy would address an $800 million market in the U.S.>>
Amgen Exec: Four Pipeline Drugs To Deliver Future Growth
Dow Jones Newswires
NEW YORK -- Amgen Inc. (AMGN) Chief Financial Officer Kate Falberg expects the company's most advanced drug candidates to deliver "real growth" in the future...
Filed in late 1999 for U.S. Food and Drug Administration approval, NESP is Amgen's next-generation version of its blockbuster anti-anemia drug Epogen, which treats dialysis patients in the U.S. With NESP, Amgen believes it can access a larger patient population, both geographically and therapeutically. It estimates the value of this worldwide market, comprising both dialysis and pre-dialysis patients, at $5 billion. In 1999, Epogen had $1.8 billion in sales.
Amgen expects to hear word from the FDA on IL-1ra, an interleukin-2 blocker, which was also filed for regulatory approval in 1999. When the drug is launched, Amgen believes it will address a $2 billion market in the U.S. and Europe, according to Falberg.
With Praecis Pharmaceuticals Inc. (PRCS), Amgen expects to have FDA approval of abarelix, a treatment for prostate cancer and endometriosis. Amgen anticipates this therapy would address an $800 million market in the U.S.
Falberg also expects FDA approval and the subsequent launch of SD/01, a next-generation version of Neupogen.
-By Beth Mantz, Dow Jones Newswires; 201-938-5287
interactive.wsj.com^PRCS |
